TARO-DILTIAZEM T CAPSULE (EXTENDED RELEASE)

País: Canadá

Língua: inglês

Origem: Health Canada

Ingredientes ativos:

DILTIAZEM HYDROCHLORIDE

Disponível em:

TARO PHARMACEUTICALS INC

Código ATC:

C08DB01

DCI (Denominação Comum Internacional):

DILTIAZEM

Dosagem:

300MG

Forma farmacêutica:

CAPSULE (EXTENDED RELEASE)

Composição:

DILTIAZEM HYDROCHLORIDE 300MG

Via de administração:

ORAL

Unidades em pacote:

90

Tipo de prescrição:

Prescription

Área terapêutica:

MISCELLANEOUS CALCIUM-CHANNEL BLOCKING AGENTS

Resumo do produto:

Active ingredient group (AIG) number: 0115863008; AHFS:

Status de autorização:

APPROVED

Data de autorização:

2015-07-24

Características técnicas

_TARO-DILTIAZEM T (DILTIAZEM HYDROCHLORIDE EXTENDED-RELEASE CAPSULES)
_
_ _
_ _
_PAGE 1 OF 41 _
PRODUCT MONOGRAPH
INCLUDING PATIENT MEDICATION INFORMATION
PR
TARO-DILTIAZEM T
Diltiazem Hydrochloride Extended-Release Capsules
Extended-Release Capsules, 120 mg, 180 mg, 240 mg, 300 mg and 360 mg,
Oral
USP
Antihypertensive Agent
Antianginal Agent
Taro Pharmaceuticals Inc.
Date of Initial Authorization:
130 East Drive, Brampton
July 24, 2015
Ontario L6T 1C1
Date of Revision:
March 10, 2023
Submission Control No: 268426
_TARO-DILTIAZEM T (DILTIAZEM HYDROCHLORIDE EXTENDED-RELEASE CAPSULES)
_
_ _
_ _
_PAGE 2 OF 41 _
RECENT MAJOR LABEL CHANGES
2. CONTRAINDICATIONS
03/2023
TABLE OF CONTENTS
SECTIONS OR SUBSECTIONS THAT ARE NOT APPLICABLE AT THE TIME OF
AUTHORIZATION ARE NOT LISTED.
RECENT MAJOR LABEL CHANGES
.................................................................................................
2
TABLE OF
CONTENTS....................................................................................................................
2
PART I: HEALTH PROFESSIONAL INFORMATION
...........................................................................
4
1
INDICATIONS........................................................................................................................
4
1. 1
Pediatrics
.......................................................................................................................
4
1. 2
Geriatrics
.......................................................................................................................
4
2
CONTRAINDICATIONS
..........................................................................................................
4
4
DOSAGE AND ADMINISTRATION
..........................................................................................
5
4. 1
Dosing Considerations
....................................................................................................
5
4. 2
Recommended Dose and Dosage Adjustment
................................................